Plavix benefit found in heart failure patients

	Tweet

Patients with heart failure who have had a heart attack but not had artery-clearing Angioplasty treatment are less likely to die early if they take the anti-clotting drug Plavix, study data showed on Monday.

The study by Danish scientists published in the Journal of the American College of Cardiology was the first to look at the effect of Plavix, known generically as clopidogrel, on death rates in specific high-risk patients with heart failure and heart attack.

Heart failure is a type of heart disease in which the heart is unable to pump enough blood around the body. Angioplasty is a non-surgical procedure to clear blocked arteries.

Because the value of using clopidogrel for heart failure patients had been long debated, the positive impact seen in the study was “of unquestionable practical importance,” researcher Victor Serebruany with the HeartDrug Research Laboratories at John Hopkins University in the United States said in a commentary on the findings.

The findings should bolster Plavix - the world’s second biggest-selling drug - which got a knock back on March 12 when U.S. regulators said it should carry a new warning on its label about patients who have a poor response to it.

Comparing groups of specific high-risk patients, researchers found that after 18 months, 32.2 percent died in the group that was not treated with Plavix versus 28.1 percent in the group that did receive it.

The results suggest that better awareness of Plavix’s benefits in such high-risk patients could have “considerable clinical impact,” the researchers wrote.

The drug is recommended to be given with aspirin to all patients who suffer heart attack, except those with an increased risk of bleeding, the researchers said.

“Despite these guidelines, however, no analyses have been done specifically on acute heart attack patients with heart failure,” they wrote, leaving doctors uncertain about how to best treat such patients.

The researchers used data from the Danish National Patient Register to create four patient groups from 31,251 patients hospitalized between 2000 and 2005.

They looked at two groups with heart failure - one receiving Plavix and one not, and two without heart failure - one receiving Plavix and one not.

They assessed the heart failure groups after 1.5 years and the non-heart failure groups after 2.05 years.

In patients without heart failure, Plavix had no effect on death rates, which were just over 9 percent in both groups, but its effect in the high-risk groups was significant.

SOURCE: Journal of the American College of Cardiology, March 30, 2010.

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]